Log in

NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, Forecast & News

$5.56
+0.06 (+1.09 %)
(As of 12/13/2019 09:07 AM ET)
Today's Range
$5.43
Now: $5.56
$5.68
50-Day Range
$4.65
MA: $5.31
$6.13
52-Week Range
$3.60
Now: $5.56
$9.76
Volume67,801 shs
Average Volume102,791 shs
Market Capitalization$65.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$4.89 per share

Profitability

Net Income$-25,870,000.00

Miscellaneous

Employees24
Market Cap$65.61 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.


Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals's stock reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.07. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

2 brokerages have issued 1-year price targets for Catabasis Pharmaceuticals' stock. Their forecasts range from $18.00 to $77.00. On average, they anticipate Catabasis Pharmaceuticals' stock price to reach $51.67 in the next twelve months. This suggests a possible upside of 829.3% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.

What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News stories about CATB stock have trended negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Catabasis Pharmaceuticals.

Are investors shorting Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 630,200 shares, an increase of 12.5% from the September 30th total of 560,000 shares. Based on an average daily volume of 79,000 shares, the short-interest ratio is presently 8.0 days. Approximately 5.8% of the company's stock are short sold. View Catabasis Pharmaceuticals' Current Options Chain.

Who are some of Catabasis Pharmaceuticals' key competitors?

What other stocks do shareholders of Catabasis Pharmaceuticals own?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)
  • Mr. Noah Clauser, VP of Fin. & Controller
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Oppenheimer & Co. Inc. (0.69%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Which major investors are buying Catabasis Pharmaceuticals stock?

CATB stock was acquired by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc.. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $5.56.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $65.61 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-25,870,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Catabasis Pharmaceuticals employs 24 workers across the globe.View Additional Information About Catabasis Pharmaceuticals.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is http://www.catabasis.com/.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High Street Floor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  437 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  751
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel